Lifecore Biomedical (NASDAQ:LFCR) Price Target Raised to $6.00

Lifecore Biomedical (NASDAQ:LFCR) had its price target upped by Barrington Research from $5.50 to $6.00 in a report issued on Wednesday,Benzinga reports. Barrington Research currently has an outperform rating on the stock.

Other analysts have also recently issued research reports about the company. Zacks Research upgraded Lifecore Biomedical to a “hold” rating in a research report on Thursday, January 1st. Weiss Ratings reiterated a “sell (d)” rating on shares of Lifecore Biomedical in a research report on Tuesday, April 21st. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Lifecore Biomedical presently has an average rating of “Hold” and a consensus target price of $6.00.

Lifecore Biomedical Price Performance

Lifecore Biomedical stock opened at $5.26 on Wednesday. Lifecore Biomedical has a 1-year low of $3.63 and a 1-year high of $8.98. The stock has a market cap of $197.14 million, a PE ratio of -5.37 and a beta of 1.08. The stock’s fifty day moving average is $5.33 and its two-hundred day moving average is $6.84.

Lifecore Biomedical (NASDAQ:LFCR) last posted its quarterly earnings results on Monday, March 16th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.05). Lifecore Biomedical had a negative net margin of 23.08% and a negative return on equity of 1,211.09%. The business had revenue of $35.75 million during the quarter, compared to analyst estimates of $35.31 million. On average, research analysts expect that Lifecore Biomedical will post -0.88 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Lifecore Biomedical

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Quarry LP purchased a new position in shares of Lifecore Biomedical during the third quarter worth about $28,000. BNP Paribas Financial Markets grew its holdings in shares of Lifecore Biomedical by 92.7% during the third quarter. BNP Paribas Financial Markets now owns 5,791 shares of the company’s stock worth $43,000 after buying an additional 2,786 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in shares of Lifecore Biomedical during the fourth quarter worth about $50,000. SG Americas Securities LLC purchased a new position in shares of Lifecore Biomedical during the first quarter worth about $64,000. Finally, State of Wyoming purchased a new position in shares of Lifecore Biomedical during the second quarter worth about $69,000. Hedge funds and other institutional investors own 83.36% of the company’s stock.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc is a publicly traded specialty biopharmaceutical company headquartered in Chaska, Minnesota. The company focuses on the development, manufacture and commercialization of hyaluronic acid (HA)–based products that address medical and aesthetic needs. Lifecore’s proprietary HA formulations are designed to meet strict regulatory standards for purity, consistency and performance in highly regulated markets.

The company’s product portfolio spans multiple therapeutic areas, including ophthalmology, orthopedics, dermatology and wound care.